Trial reportCNS drugs2026
Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study.
Trial report in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05875974 (A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesJazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) was a phase 4, prospective, multicenter, single-arm, open-label, multiple-cohort study of individuals with idiopathic hypersomnia or narcolepsy evaluating safety and effectiveness of low-sodium oxybate (LXB; Xywav
methodsThe DUET study included a screening period (with a 2-week washout for current oxybate users), an 8-day baseline (BL) period, a 2- to 8-week LXB titration period, a 2-week stable-dose period, an 8-day end-of-treatment period (EOT) period, and a 2-week safety follow-up. The primary endpoint was the change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Secondary endpoints for the idiopathic hypersomnia cohort included change in Idiopathic Hypersomnia Severity Scale (IHSS) total score; Patient Global Impression of Change (PGI-C) and Severity (PGI-S) for overall idiopathic hypersomnia disease, sleep inertia, and fatigue; and changes in sleep quality and feeling rested upon awakening (from self-reported daily sleep diary). Exploratory outcomes included sleep patterns measured by actigraphy, the British Columbia Cognitive Complaints Inventory, Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10), and Work Productivity and Activity Impairment Questionnaire: Specific Health Problem. Incidence and severity of treatment-emergent adverse events (TEAEs) were assessed.
resultsForty-six participants with idiopathic hypersomnia enrolled and took LXB for ≥ 1 night after the BL period; n = 40 completed. Most enrolled participants were female (80.4%), White (84.8%), and non-Hispanic/Latino (76.1%), with mean (SD) age of 38.1 (11.8) years; 19 (41.3%) were taking concomitant alerting agents. Least squares mean (LSM; standard error [SE]) changes in ESS score and IHSS total score from BL to EOT were - 8.4 (0.7), p < 0.0001, and - 15.5 (1.5), p < 0.0001, respectively. On the PGI-C at EOT, most participants (94.6%; 95% CI 81.8, 99.3) reported improvement in overall idiopathic hypersomnia disease. Additionally, participants showed improvements (BL vs EOT) in sleep quality (36.7% vs 6.7% reporting "poor" or "very poor") and level of feeling rested upon awakening (73.3% vs 26.7% reporting "slightly" or "not at all rested"), and number of awakenings on actigraphy (LSM [SE] change - 3.4 [0.6], p < 0.0001). Participants also exhibited improved daytime functioning in parallel with reduced nocturnal sleep time. From BL to EOT, LS mean (SE) changes for work time missed, impairment while working, overall work impairment, and activity impairment were - 4.6% (1.8%), p = 0.0179; - 30.7% (3.9%), p < 0.0001; - 32.4% (4.3%), p < 0.0001; and - 37.3% (4.3%), p < 0.0001, respectively. Treatment-emergent adverse events (occurring in ≥ 10% of participants) included nausea (19.6%), dizziness (17.4%), headache (17.4%), and vomiting (10.9%).
conclusionsIndividuals with idiopathic hypersomnia treated with open-label LXB showed improvements in subjective and objective measures of sleep and symptoms. Treatment-emergent adverse events were consistent with the known safety profile of LXB. This study supports the effectiveness of LXB in treating this condition with a 24-h burden of symptoms. CLINICAL
trial registrationClinicalTrials.gov NCT05875974. [Graphical abstract available].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.